Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT, Limoges, France.

Published: December 2024

Background: In sub-Saharan Africa (SSA), the number of people living with dementia is expected to double every 20 years, from 2.7 to 7.6 million. Understanding beliefs, perceptions and experiences relating to dementia, care, and help-seeking are critical to understanding the nature of the problem and designing research programmes, interventions and services which meet locally defined needs. We carried out a systematic review of the scientific qualitative evidence on the perceptions and experience of living with dementia in SSA.

Method: We conducted a systematic review of qualitative studies (open-ended in-depth interviews, focus-group discussions and ethnographic methods) including people living with dementia (PLWD), family caregivers of PLWD, paid caregivers, healthcare workers, traditional and faith healers with experience of treating PLWD, and community members. The search strategy to identify relevant articles used the search terms "(dementia OR Alzheimers)" AND "(qualitative OR anthrop* OR ethnog* OR cultural OR understand* OR belie* OR experien* OR phenomenol*) AND "(Africa OR sub-Saharan Africa OR [list of countries included in SSA according to World Bank definition]), in eight databases (PubMed, BiblioInserm, PsycINFO, PsycARTICLE, Web of science, Google Scholar, IENT et DATAD - Database of African Theses and Dissertation). A thematic synthesis approach was then used.

Result: The search retrieved 4967 abstracts. Following abstract screening and full-text assessment, 16 studies were eligible from 10 different countries (South Africa, Tanzania, Nigeria, Ghana, Republic of Congo, Central African Republic, Kenya, Ethiopia, Uganda, and Burkina Faso). Overall, there was a lack of awareness of dementia among the community and no equivalent term for dementia was identified in any local languages. Often it was believed that although not experienced by everyone, dementia-like symptoms were part of "normal ageing". Participants frequently reported problems with memory and communication as well as problems typically associated with co-morbidities of old age (pain, sight/hearing problems).

Conclusion: Qualitative evidence regarding dementia perceptions and experiences in African populations remains limited compared to quantitative evidence. Findings suggest that there is a desire to gain a better understanding of the lived experience of dementia, which is essential to design culturally sensitive education, to counteract stigma and to enhance management of the condition.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.093077DOI Listing

Publication Analysis

Top Keywords

living dementia
12
dementia
9
dementia care
8
sub-saharan africa
8
people living
8
perceptions experiences
8
systematic review
8
qualitative evidence
8
care psychosocial
4
psychosocial factors
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Cognition Therapeutics, Purchase, NY, USA.

Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NA, Charlottesville, VA, USA.

Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.

View Article and Find Full Text PDF

Introduction: The United States is undergoing a demographic shift with increasing proportions of older adults. Currently, one in three older adults pass away with a form of Alzheimer's disease or related dementias (ADRD). This figure is higher in underrepresented and underserved groups including older adults in rural Appalachian communities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!